The monoacylglycerol lipase inhibitorJZL184 attenuatesLPS‐induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action
Authors:
- 27 May 2013
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 169 (4) , 808-819
Abstract
Background and purpose: JZL184 is a selective inhibitor of monoacylglycerol lipase (MAGL), the enzyme that preferentially catabolizes the endocannabinoid 2‐arachidonoyl glycerol (2‐AG). Here, we have studied the effects ofJZL184 on inflammatory cytokines in the brain and plasma following an acute immune challenge and the underlying receptor and molecular mechanisms involved.Experimental approach: JZL184 and/or theCB1receptor antagonist,AM251 or theCB2receptor antagonist,AM630 were administered to rats 30 min before lipopolysaccharide (LPS). 2 h later cytokine expression and levels,MAGLactivity, 2‐AG, arachidonic acid and prostaglandin levels were measured in the frontal cortex, plasma and spleen.Key results: JZL184 attenuatedLPS‐induced increases inIL‐1β,IL‐6,TNF‐α andIL‐10 but not the expression of the inhibitor ofNFkB(IκBα) in rat frontal cortex.AM251 attenuatedJZL184‐induced decreases in frontal corticalIL‐1β expression. Although arachidonic acid levels in the frontal cortex were reduced inJZL184‐treated rats,MAGLactivity, 2‐AG,PGE2andPGD2were unchanged. In comparison,MAGLactivity was inhibited and 2‐AGlevels enhanced in the spleen followingJZL184. In plasma,LPS‐induced increases inTNF‐α andIL‐10 levels were attenuated byJZL184, an effect partially blocked byAM251. In addition,AM630 blockedLPS‐induced increases in plasmaIL‐1β in the presence, but not absence, ofJZL184.Conclusion and implications: Inhibition of peripheralMAGLin rats byJZL184 suppressedLPS‐induced circulating cytokines that in turn may modulate central cytokine expression. The data provide further evidence for the endocannabinoid system as a therapeutic target in treatment of central and peripheral inflammatory disorders.Linked Articles: This article is part of a themed section on Cannabinoids. To view the other articles in this section visithttp://dx.doi.org/10.1111/bph.2013.169.issue‐4&http://dx.doi.org/10.1111/bph.2012.167.issue‐8Keywords
This publication has 64 references indexed in Scilit:
- Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote NeuroinflammationScience, 2011
- Guide to Receptors and Channels (GRAC), 5th editionBritish Journal of Pharmacology, 2011
- A role for the ventral hippocampal endocannabinoid system in fear-conditioned analgesia and fear responding in the presence of nociceptive tone in ratsPain, 2011
- Inhibition of Monoacylglycerol Lipase Attenuates Nonsteroidal Anti-Inflammatory Drug-Induced Gastric Hemorrhages in MiceThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in ratsPharmacological Research, 2011
- PPARγ agonist rosiglitazone ameliorates LPS-induced inflammation in vascular smooth muscle cells via the TLR4/TRIF/IRF3/IP-10 signaling pathwayCytokine, 2011
- Increasing endogenous 2‐arachidonoylglycerol levels counteracts colitis and related systemic inflammationThe FASEB Journal, 2011
- Inhibition of COX‐2 expression by endocannabinoid 2‐arachidonoylglycerol is mediated via PPAR‐γBritish Journal of Pharmacology, 2011
- The activity of the endocannabinoid metabolising enzyme fatty acid amide hydrolase in subcutaneous adipocytes correlates with BMI in metabolically healthy humansLipids in Health and Disease, 2011
- Blockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic PainThe Journal of Pharmacology and Experimental Therapeutics, 2009